Recent News

• 11.04.2026 - Geron Corporation to Present Data Highlighting Clinical and Biological Activity of RYTELO® (imetelstat) at ASH 2026
• 11.04.2026 - Geron Corporation Reports Third Quarter 2026 Financial Results and Recent Business Highlights
• 11.03.2026 - Geron Corporation to Participate in the Stifel 2026 Healthcare Conference
• 10.28.2026 - Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis
• 10.21.2026 - Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026
• 10.19.2026 - Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 10.12.2026 - Geron Corporation Announces Oral Presentations Highlighting Imetelstat at International Hematology Congresses in Europe and Asia
• 09.18.2026 - Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 09.02.2026 - Geron to Present at Upcoming Investor Conferences
• 08.18.2026 - Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

• 11.04.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.04.2026 - EX-99.1 EX-99.1
• 11.04.2026 - 8-K Current report
• 10.28.2026 - 8-K Current report
• 10.28.2026 - EX-99.1 EX-99.1
• 10.01.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.14.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.07.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.06.2026 - 8-K Current report
• 08.06.2026 - EX-99.1 EX-99.1